Coherus BioSciences, Inc. (CHRS) EPS Estimated At $-0.40 on May, 9

Coherus BioSciences, Inc. (NASDAQ:CHRS) Corporate Logo
Big Money Sentiment increased to 1.29 in Q4 2018. It has change of 0.18, from 2018Q3’s 1.11. The ratio improved due to Coherus BioSciences, Inc. positioning: 17 sold and 25 reduced. 22 funds acquired stakes and 32 increased stakes. Investors holded 59.61 million in 2018Q3 but now own 59.12 million shares or 0.82% less.
Moreover, Tiverton Asset Mngmt Ltd Limited Liability Company has 0% invested in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 3,406 shs. New York-based D E Shaw has invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Swiss Bancorp holds 0% of its capital in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 78,000 shs. 33,060 were accumulated by Boston Limited Liability. Hightower Advsr Lc holds 11,450 shs. Moreover, State Street has 0% invested in Coherus BioSciences, Inc. (NASDAQ:CHRS). Bnp Paribas Arbitrage reported 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Aqr Cap Lc has 39,425 shs. Sectoral Asset Management owns 27,987 shs or 0.03% of their US capital. Tiaa Cref Limited Co invested in 0.01% or 1.17 million shs. Huntington Natl Bank holds 1 shs or 0% of its capital. 650,544 are held by Northern. Jefferies Gru Ltd Limited Liability Company has 10,060 shs for 0% of their capital. Jacobs Levy Equity owns 50,486 shs or 0.01% of their US capital. The New York-based Bluemountain Cap Management Ltd Liability has invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS).

On May, 9 WallStreet expected Coherus BioSciences, Inc. (NASDAQ:CHRS)’s earnings release, as reported by Faxor. Analysts expect change of 45.95 % or $0.34 from previous year’s $-0.74 EPS compared to current’s $-0.40 EPS. Wall Street forecasts -56.52 % EPS growth as of May, 9. CHRS hit $14.49 during the last trading session after $0.56 change.Coherus BioSciences, Inc. has 1.50 million shares volume, 97.33% up from normal. CHRS is uptrending and has moved 53.37% since April 6, 2018. CHRS outperformed by 49.00% the S&P500.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Coverage

In total 2 analysts cover Coherus Biosciences (NASDAQ:CHRS). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:CHRS) has 100% bullish analysts. 2 are the (NASDAQ:CHRS)’s ratings reports on Apr 6, 2019 according to StockzIntelligence Inc. On Thursday, March 7 the stock of Coherus BioSciences, Inc. (NASDAQ:CHRS) has “Buy” rating given by Credit Suisse. On Friday, March 1 Maxim Group maintained Coherus BioSciences, Inc. (NASDAQ:CHRS) with “Buy” rating.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide.The firm is valued at $1.00 billion. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non?small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma.Last it reported negative earnings. The Company’s product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

For more Coherus BioSciences, Inc. (NASDAQ:CHRS) news brought out recently go to: Seekingalpha.com, Globenewswire.com, Globenewswire.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Coherus sees up to $38M in Q1 Udenyca sales; shares up 5% after hours – Seeking Alpha” brought out on April 05, 2019, “Coherus BioSciences Announces New Employment Inducement Grants – GlobeNewswire” on March 19, 2019, “Coherus BioSciences Receives European Commission Approval for UDENYCAâ„¢ (Pegfilgrastim Biosimilar) – GlobeNewswire” with a publish date: September 25, 2018, “Coherus sues Amgen over Humira biosimilar – Seeking Alpha” and the last “Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: November 08, 2018.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.